AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase II study titled Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy. The study aims to evaluate the efficacy and safety of combining durvalumab and bevacizumab with transarterial radioembolization (TARE) in patients with unresectable hepatocellular carcinoma (HCC) that can be treated with embolization. This research is significant as it explores a potential new treatment avenue for HCC, a challenging cancer type.
Intervention/Treatment: The study tests an experimental combination of treatments: durvalumab and bevacizumab, both administered intravenously, following TARE using Yttrium-90 glass microspheres. This approach aims to improve outcomes in HCC patients by leveraging the strengths of immunotherapy and targeted embolization.
Study Design: This is an interventional study with a single-group assignment. There is no random allocation or masking involved, as all participants receive the same treatment. The primary purpose is to assess the treatment’s effectiveness and safety in a clinical setting.
Study Timeline: The study began on September 11, 2023, with recruitment currently ongoing. The primary completion and estimated study completion dates are not specified, but the last update was submitted on August 28, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
Market Implications: This study update could influence AstraZeneca’s stock performance positively if the results show significant efficacy and safety, potentially boosting investor confidence. The study’s focus on HCC, a competitive area in oncology, might also impact the strategies of competitors in the pharmaceutical industry, who may need to adjust their research and development priorities.
The study is ongoing, and further details are available on the ClinicalTrials portal.